X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-04-17 | FENC | Fennec Pharmaceuticals Inc. | Haigh Adrian | COO | S - Sale+OE | $6.04 | -88,888 | 0 | -100% | -$536,661 | |||||
| D | 2024-04-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $25.74 | -1,750 | 1,737 | -50% | -$45,045 | |||||
| D | 2024-04-16 | AVTE | Aerovate Therapeutics, Inc. | Noyes Timothy P | CEO | S - Sale+OE | $24.70 | -10,000 | 0 | -100% | -$246,971 | |||||
2024-04-16 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $7.66 | -11,447 | 7,229,861 | 0% | -$87,725 | ||||||
| DM | 2024-04-16 | RXRX | Recursion Pharmaceuticals, Inc. | Secora Michael | CFO | S - Sale+OE | $7.63 | -48,124 | 1,231,055 | -4% | -$367,007 | |||||
| M | 2024-04-16 | GNLX | Genelux Corp | Szalay Aladar | 10% | S - Sale | $3.59 | -71,420 | 4,113,885 | -2% | -$256,227 | |||||
| D | 2024-04-16 | ALXO | Alx Oncology Holdings Inc | Pons Jaume | Pres, CSO | S - Sale+OE | $14.20 | -50,000 | 604,205 | -8% | -$710,195 | |||||
2024-04-18 | ZTS | Zoetis Inc. | Lagano Roxanne | EVP | S - Sale | $151.17 | -923 | 15,602 | -6% | -$139,530 | ||||||
| D | 2024-04-17 | CSWI | Csw Industrials, Inc. | Armes Joseph B | COB, Pres, CEO | S - Sale+OE | $232.69 | -1,000 | 61,124 | -2% | -$232,686 | |||||
2024-04-17 | STOK | Stoke Therapeutics, Inc. | Skorpios Trust | 10% | S - Sale | $11.60 | -3,600,000 | 10,843,681 | -25% | -$41,760,000 | ||||||
| M | 2024-04-16 | CMPS | Compass Pathways Plc | Goldsmith George Jay | 10% | S - Sale | $8.61 | -69,461 | 7,949,073 | -1% | -$597,964 | |||||
| M | 2024-04-16 | CMPS | Compass Pathways Plc | Malievskaia Ekaterina | 10% | S - Sale | $8.61 | -69,461 | 7,949,073 | -1% | -$597,964 | |||||
| D | 2024-04-16 | ACLX | Arcellx, Inc. | Ware Olivia C | Dir | S - Sale+OE | $55.55 | -9,402 | 0 | -100% | -$522,260 | |||||
| D | 2024-04-15 | OTLK | Outlook Therapeutics, Inc. | Syntone Ventures LLC | 10% | P - Purchase | $0.00 | +714,286 | 1,705,438 | +72% | +$0 | |||||
2024-04-11 | BCEL | Atreca, Inc. | Orwin John A | Pres, CEO | P - Purchase | $0.01 | +1 | 77,542 | 0% | +$0 | ||||||
| DM | 2024-04-16 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | S - Sale+OE | $38.42 | -20,000 | 168,176 | -11% | -$768,390 | |||||
2024-04-16 | PROK | Prokidney Corp. | Weber Darin J. | SVP of Regulatory Development | S - Sale | $2.50 | -17,238 | 172,432 | -9% | -$43,095 | ||||||
2024-04-16 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.28 | -100,000 | 12,546,116 | -1% | -$928,005 | ||||||
2024-04-16 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.28 | -100,000 | 12,546,116 | -1% | -$928,005 | ||||||
| D | 2024-04-15 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $59.91 | -19,582 | 408,122 | -5% | -$1,173,232 | |||||
| D | 2024-04-15 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $133.37 | -19,818 | 40,778 | -33% | -$2,643,020 | |||||
| D | 2024-04-16 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $41.60 | -4,006 | 21,271 | -16% | -$166,641 | |||||
| D | 2024-04-16 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale+OE | $41.66 | -905 | 46,156 | -2% | -$37,698 | |||||
2024-04-15 | DNLI | Denali Therapeutics Inc. | Sato Vicki L | Dir | S - Sale | $18.29 | -1,666 | 118,043 | -1% | -$30,471 | ||||||
| D | 2024-04-15 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $18.19 | -15,000 | 408,035 | -4% | -$272,871 | |||||
2024-04-15 | NUVL | Nuvalent, Inc. | Shair Matthew | Dir | S - Sale | $65.56 | -37,500 | 1,813,220 | -2% | -$2,458,335 | ||||||
| D | 2024-04-15 | NUVL | Nuvalent, Inc. | Conley Emily | Dir | S - Sale+OE | $65.52 | -5,000 | 8 | -100% | -$327,607 | |||||
| D | 2024-04-15 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Chief Med, Dev Officer | S - Sale+OE | $44.47 | -14,375 | 27,786 | -34% | -$639,256 | |||||
2024-04-16 | RVNC | Revance Therapeutics, Inc. | Jordan Erica | Chief Commercial Officer | S - Sale | $3.80 | -2,392 | 114,864 | -2% | -$9,096 | ||||||
| M | 2024-04-15 | ANIP | Ani Pharmaceuticals Inc | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS | S - Sale | $65.91 | -22,768 | 883,504 | -3% | -$1,500,589 | |||||
| DM | 2024-04-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $233.73 | -7,200 | 130 | -98% | -$1,682,819 | |||||
2024-04-15 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $61.24 | -341 | 63,239 | -1% | -$20,883 | ||||||
2024-04-16 | WDFC | Wd 40 Co | Brass Steven A | Pres, CEO | P - Purchase | $232.22 | +432 | 20,547 | +2% | +$100,319 | ||||||
2024-04-15 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $7.06 | -7,500 | 1,336,297 | -1% | -$52,924 | ||||||
2024-04-15 | ELF | E.L.F. Beauty, Inc. | Franks Joshua Allen | SVP, Operations | S - Sale | $165.16 | -727 | 83,736 | -1% | -$120,071 | ||||||
| A | 2024-04-04 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $15.50 | +193,548 | 616,541 | +46% | +$2,999,994 | |||||
| A | 2024-03-12 | ALDX | Aldeyra Therapeutics, Inc. | Machatha Stephen | Chief Development Officer | S - Sale | $3.16 | -11,537 | 252,812 | -4% | -$36,503 | |||||
| A | 2024-04-04 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $15.50 | +193,548 | 616,541 | +46% | +$2,999,994 | |||||
| A | 2024-03-11 | ALDX | Aldeyra Therapeutics, Inc. | Greenberg Bruce | See Remarks | S - Sale | $3.41 | -13,201 | 130,154 | -9% | -$44,968 | |||||
2024-04-17 | NEOG | Neogen Corp | Jones Douglas Edward | COO | P - Purchase | $12.36 | +10,000 | 46,131 | +28% | +$123,590 | ||||||
| DM | 2024-04-15 | FENC | Fennec Pharmaceuticals Inc. | Haigh Adrian | COO | S - Sale+OE | $6.30 | -88,888 | 0 | -100% | -$559,848 | |||||
| DM | 2024-04-12 | RCKT | Rocket Pharmaceuticals, Inc. | Southwell David P | Dir | S - Sale+OE | $24.32 | -80,000 | 114,784 | -41% | -$1,945,785 | |||||
2024-04-12 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale | $14.58 | -2,060 | 500,527 | 0% | -$30,035 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $14.58 | -1,525 | 213,321 | -1% | -$22,235 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale | $14.58 | -1,585 | 151,881 | -1% | -$23,109 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale | $14.58 | -3,136 | 315,045 | -1% | -$45,723 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $14.58 | -8,360 | 2,415,247 | 0% | -$121,889 | ||||||
| M | 2024-04-01 | PROK | Prokidney Corp. | Weber Darin J. | SVP of Regulatory Development | S - Sale | $1.73 | -84,403 | 189,670 | -31% | -$146,005 | |||||
2024-04-15 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale | $105.02 | -15,000 | 1,642,290 | -1% | -$1,575,300 | ||||||
2024-04-09 | CLNN | Clene Inc. | General Resonance LLC | 10% | S - Sale | $0.39 | -22,500 | 15,428,212 | 0% | -$8,675 | ||||||
| DM | 2024-03-20 | PKTX | Protokinetix, Inc. | Smith Clarence Edward | Pres, CEO, 10% | P - Purchase | $0.01 | +3,166,667 | 77,137,093 | +4% | +$35,000 | |||||
| D | 2024-04-12 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $14.58 | -1,189 | 111,537 | -1% | -$17,336 | |||||
| D | 2024-04-11 | OCX | Oncocyte Corp | Broadwood Partners, L.P. | 10% | P - Purchase | $2.92 | +2,420,000 | 9,858,289 | +33% | +$7,057,688 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $25.03 | -17,500 | 394,027 | -4% | -$438,099 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | S - Sale+OE | $25.04 | -30,000 | 1,117,035 | -3% | -$751,332 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale+OE | $25.04 | -47,709 | 1,264,587 | -4% | -$1,194,700 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $24.72 | -14,000 | 0 | -100% | -$346,149 | |||||
| M | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $24.11 | -6,964 | 203,129 | -3% | -$167,888 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief Medical Officer | S - Sale+OE | $25.07 | -20,000 | 0 | -100% | -$501,478 | |||||
2024-04-12 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $67.79 | -250 | 59,731 | 0% | -$16,948 | ||||||
| D | 2024-04-11 | IRON | Disc Medicine, Inc. | White William Richard | Dir | S - Sale+OE | $31.80 | -2,560 | 0 | -100% | -$81,407 | |||||
| D | 2024-04-15 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $10.45 | -800 | 45,838 | -2% | -$8,360 | |||||
| DM | 2024-04-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $237.19 | -7,200 | 130 | -98% | -$1,707,775 | |||||
| DM | 2024-04-11 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | Dir | S - Sale+OE | $91.13 | -40,000 | 722,527 | -5% | -$3,645,000 | |||||
| D | 2024-04-11 | THRD | Third Harmonic Bio, Inc. | Holles Natalie C. | CEO | S - Sale+OE | $12.19 | -13,558 | 1,218,836 | -1% | -$165,214 | |||||
2024-04-11 | ACRV | Acrivon Therapeutics, Inc. | Perceptive Advisors LLC | 10% | P - Purchase | $8.50 | +2,353,000 | 5,360,858 | +78% | +$20,000,500 | ||||||
2024-04-11 | OCX | Oncocyte Corp | Riggs Josh | CEO, Pres | P - Purchase | $2.95 | +3,390 | 3,505 | >999% | +$10,001 | ||||||
2024-04-11 | OCX | Oncocyte Corp | Arno Andrew | Dir | P - Purchase | $2.95 | +33,898 | 84,662 | +67% | +$99,999 | ||||||
2024-04-10 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $35.40 | -17,500 | 810,850 | -2% | -$619,467 | ||||||
| DM | 2024-04-10 | LGVN | Longeveron Inc. | Hare Joshua | Chief Scientific Officer, 10% | P - Purchase | $2.35 | +148,936 | 633,280 | +31% | +$350,000 | |||||
| D | 2024-04-11 | LGVN | Longeveron Inc. | Hashad Mohamed Wa'El Ahmed | CEO | P - Purchase | $2.35 | +10,638 | 19,616 | +118% | +$24,999 | |||||
| DM | 2024-04-10 | LGVN | Longeveron Inc. | Soffer Rock | Dir | P - Purchase | $2.35 | +138,298 | 208,534 | +197% | +$325,000 | |||||
2024-04-10 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $107.12 | -15,000 | 11,737,969 | 0% | -$1,606,865 | ||||||
| DM | 2024-04-10 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | S - Sale+OE | $23.36 | -67,000 | 22,341 | -75% | -$1,564,812 | |||||
| D | 2024-04-10 | AVTE | Aerovate Therapeutics, Inc. | Eldridge George A | SEE REMARKS | S - Sale+OE | $26.85 | -7,500 | 1,960 | -79% | -$201,392 | |||||
2024-04-11 | BCYC | Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson | CHIEF PROD, SUPPLY CHAIN OFF | S - Sale | $22.49 | -257 | 22,891 | -1% | -$5,780 | ||||||
| D | 2024-04-10 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | S - Sale+OE | $37.00 | -2,155 | 15,700 | -12% | -$79,735 | |||||
2024-04-12 | WDFC | Wd 40 Co | Pendarvis David | Dir | P - Purchase | $234.75 | +328 | 4,934 | +7% | +$76,998 | ||||||
2024-04-11 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $6.74 | -54 | 70,849 | 0% | -$364 | ||||||
2024-04-10 | VERA | Vera Therapeutics, Inc. | Young Joseph R | SVP, Finance, Chief Acct Offcr | S - Sale | $40.00 | -5,714 | 53,171 | -10% | -$228,560 | ||||||
2024-04-10 | BMRN | Biomarin Pharmaceutical Inc | Burkhart Erin | GVP, Chief Accounting Officer | S - Sale | $90.00 | -2,286 | 16,156 | -12% | -$205,740 | ||||||
| M | 2024-04-09 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale | $149.50 | -50,000 | 47,512,317 | 0% | -$7,475,024 | |||||
2024-04-09 | AVTE | Aerovate Therapeutics, Inc. | Grayzel David S. | Dir | S - Sale | $28.15 | -11,882 | 1,799,232 | -1% | -$334,478 | ||||||
| M | 2024-04-09 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.88 | +3,188 | 1,086,279 | 0% | +$2,805 | |||||
2024-04-11 | PTN | Palatin Technologies Inc | Deveer Robert K Jr | Dir | P - Purchase | $2.12 | +6,000 | 40,845 | +17% | +$12,703 | ||||||
| DM | 2024-04-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $237.21 | -28,800 | 130 | -100% | -$6,831,737 | |||||
2024-01-02 | LIAN | Lianbio | Gu Ehong | Interim CFO | S - Sale | $4.34 | -1,731 | 0 | -100% | -$7,513 | ||||||
2024-04-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $33.16 | -556 | 74,444 | -1% | -$18,434 | ||||||
2024-04-10 | ATOS | Atossa Therapeutics, Inc. | Finn Jonathan | Dir | P - Purchase | $1.77 | +25,000 | 25,000 | New | +$44,250 | ||||||
2024-04-11 | NEOG | Neogen Corp | Borel James C | Dir | P - Purchase | $13.06 | +7,500 | 21,392 | +54% | +$97,986 | ||||||
| D | 2024-04-08 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Pres, R, D,, CMO | S - Sale+OE | $245.99 | -2,676 | 1,114,539 | 0% | -$658,258 | |||||
| D | 2024-04-08 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $246.19 | -26,270 | 841,275 | -3% | -$6,467,491 | |||||
2024-04-08 | RCKT | Rocket Pharmaceuticals, Inc. | White Mark Andrew | See Remarks | S - Sale | $24.64 | -12,532 | 75,226 | -14% | -$308,763 | ||||||
2024-04-08 | ONCT | Oncternal Therapeutics, Inc. | Wills Robert James | Dir | P - Purchase | $8.96 | +3,086 | 10,000 | +45% | +$27,655 | ||||||
2024-04-08 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $18.60 | -4,875 | 396,624 | -1% | -$90,687 | ||||||
2024-04-08 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $6.07 | +3,200 | 3,200 | New | +$19,411 | ||||||
2024-04-09 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.28 | -100,000 | 12,646,116 | -1% | -$927,735 | ||||||
2024-04-09 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.28 | -100,000 | 12,646,116 | -1% | -$927,735 | ||||||
| D | 2024-04-08 | CPRX | Catalyst Pharmaceuticals, Inc. | Tierney David S | Dir | S - Sale+OE | $15.68 | -25,000 | 348,874 | -7% | -$392,000 | |||||
2024-04-08 | NUVL | Nuvalent, Inc. | Shair Matthew | Dir | S - Sale | $68.44 | -37,500 | 1,850,720 | -2% | -$2,566,479 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |